Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies

Rheumatic Disease Clinics of North America

Volumn 28, Issue 4, 2002, Pages 859-890

  Targoff, Ira N ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; CARBONATE DEHYDRATASE III; CREATINE; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MUSCLE ENZYME; MYOGLOBIN; NEOPTERIN; RHEUMATOID FACTOR; TROPONIN;

ENZYME BLOOD LEVEL; HUMAN; IDIOPATHIC DISEASE; INFLAMMATORY DISEASE; LABORATORY DIAGNOSIS; LABORATORY TEST; MUSCLE DISEASE; MYOPATHY; PRIORITY JOURNAL; REVIEW;

AUTOANTIBODIES; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; MALE; MUSCLE, SKELETAL; MYOSITIS;

EID: 0036866050     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00032-7     Document Type: Review

References (162)

1. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995;2:1-9.
2. Askari AD, Vignos Jr PJ, Moskowitz LW. Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-92.
3. Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987;30:213-7.
4. Bessman SP. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 1985;54:831-62.
5. Black HR, Quallich H, Gareleck CB. Racial differences in serum creatine kinase levels. Am J Med 1986;81:479-87.
6. Johnston JD, Lloyd M, Mathews JA, et al. Racial variation in serum creatine kinase levels. J R Soc Med 1996;89:462-4.
7. Hinderks GJ, Frohlich J. Low serum creatine kinase values associated with administration of steroids. Clin Chem 1979;25:2050-1.
8. Sanmarti R, Collado A, Gratacos J, et al. Reduced activity of serum creatine kinase in rheumatoid arthritis: A phenomenon linked to the inflammatory response. Br J Rheumatol 1994;33:231-4.
9. Wei N, Pavlidis N, Tsokos G, et al. Clinical significance of low creatine phosphokinase values in patients with connective tissue diseases. JAMA 1981;246:1921-3.
10. Garton MJ, Isenberg DA. Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases. Br J Rheumatol 1997;36:1067-74.
11. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation: A poor prognostic sign. Am J Med 1986;80:329-32.
12. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986;15:168-78.
13. de Toro Santos FJ, Verea-Hernando H, Montero C, et al. Chronic pneumomediastinum and subcutaneous emphysema: Association with dermatomyositis. Respiration 1998;62:53-6.
14. Gran JT, Myklebust G, Johansen S. Adult idiopathic polymyositis without elevation of creatine kinase. Case report and review of the literature. Scand J Rheumatol 1993;22:94-6.
15. Koh ET, Seow A, Ong B, et al. Adult onset polymyositis/dermatomyositis: Clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993;52:857-61.
16. Matsuda Y, Tomii M, Kashiwazaki S. Fatal pneumomediastinum in dermatomyositis without creatine kinase elevation. Intern Med 1993;32:643-7.
17. Takada T, Suzuki E, Nakano M, et al. Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern Med 1998;37:669-73.
18. Felice KJ, North WA. Inclusion body myositis in Connecticut: Observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001;80:320-7.
19. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996;40:581-6.
20. Pautas E, Cherin P, Piette JC, et al. Features of polymyositis and dermatomyositis in the elderly: A case-control study. Clin Exp Rheumatol 2000;18:241-4.
21. Erlacher P, Lercher A, Falkensammer J, et al. Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. Clin Chim Acta 2001;306:27-33.
22. Kroll M, Otis J, Kagen LJ. Serum enzyme, myoglobin and muscle strength relationships in polymyositis and dermatomyositis. J Rheumatol 1986;13:349-55.
23. Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol 1996;23:1380-4.
24. Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102.
25. Dayal NA, Isenberg DA. Assessment of inflammatory myositis. Curr Opin Rheumatol 2001;13:488-92.
26. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
27. Wiesinger GF, Quittan M, Nuhr M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil 2000;81:1-5.
28. Clarkson PM, Ebbeling C. Investigation of serum creatine kinase variability after muscledamaging exercise. Clin Sci 1988;75:257-61.
29. Kosano H, Kinoshita T, Nagata N, et al. Change in concentrations of myogenic components of serum during 93 h of strenuous physical exercise. Clin Chem 1986;32:346-8.
30. Taniyama M, Yoh S, Asaba Y, et al. Elevated serum creatine kinase level in diabetic patients with nephrotic syndrome: A role of fluid retention. Ann Intern Med 1987;106:711-2.
31. Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: A noncardiac source. Ann Intern Med 1981;94:341-3.
32. Lee KN, Csako G, Bernhardt P, et al. Relevance of macro creatine kinase Type 1 and Type 2 isoenzymes to laboratory and clinical data. Clin Chem 1994;40:1278-83.
33. Bonnet S, Mercie P, Lacape G, et al. Macro-CK revelatrice d'un carcinome epidermoide dissemine du sinus piriforme chez un patient atteint de dermatomyosite. [Macro-CK disclosing disseminated epidermoid carcinoma of the pyriform sinus in a patient with dermatomyositis]. Rev Med Intern 2001;22:292-6 [in French].
34. Mandell BF. Aldolase in the diagnosis of myositis. Am J Med 1991;90:662.
35. Targoff IN. Laboratory manifestations of polymyositis/dermatomyositis. Clin Dermatol 1988;6:76-92.
36. Kagen LJ. History, physical examination, and laboratory tests in the evaluation of myopathy. In: Wortmann RL, editor. Diseases of Skeletal Muscle. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 255-66.
37. Munsat TL, Baloh R, Pearson CM, et al. Serum enzyme alterations in neuromuscular disorders. JAMA 1973;226:1536-43.
38. Helfgott SM, Karlson E, Beckman E. Misinterpretation of serum transaminase elevation in "occult" myositis. Am J Med 1993;95:447-9.
39. Ohta M, Itagaki Y, Itoh N, et al. Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: Relationship with creatine kinase. Clin Chem 1991;37:36-9.
40. Osterman PO, Askmark H, Wistrand PJ. Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run. J Neurol Sci 1985;70:347-57.
41. Vaananen HK, Takala TES, Tolonen U, et al. Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders. Arch Neurol 1988;45:1254-6.
42. Lovece S, Kagen LJ. Sensitive rapid detection of myoglobin in serum of patients with myopathy by immunoturbidimetric assay. J Rheumatol 1993;20:1331-4.
43. Wortmann RL. Skeletal muscle biology, physiology, and biochemistry. In: Wortmann RL, editor. Diseases of Skeletal Muscle. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 11-22.
44. Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995;41:1710-5.
45. Kiely PD, Bruckner FE, Nisbet JA, et al. Serum skeletal troponin I in inflammatory muscle disease: Relation to creatine kinase, CKMB and cardiac troponin I. Ann Rheum Dis 2000;59:750-1.
46. Bodor GS, Survant L, Voss EM, et al. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem 1997;43:476-84.
47. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20:857-80.
48. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
49. Reichlin M, Amett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984;27:1150-6.
50. Casciola-Rosen LA, Pluta AF, Plotz PH, et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001;44:389-96.
51. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis. [abstract] Arthritis Rheum 1997;40:S139.
52. Targoff IN, Shamim E, Sherry DD, et al. A novel dermatomyositis (DM)-associated autoantibody directed against a 155 kd protein [abstract]. Arthritis Rheum 2000;43:S175.
53. Targoff IN, Trieu EP, Sontheimer RD. Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis [abstract]. Arthritis Rheum 2000;43:S194.
54. D'Cruz D, Keser G, Khamashta MA, et al. Antiendothelial cell antibodies in inflammatory myopathies, distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol 2000;27:161-4.
55. Feist E, Dorner T, Kuckelkorn U, et al. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996;184:1313-8.
56. Uthman I, Vazquez-Abad D, Senecal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996;26:447-58.
57. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: Pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000;68:472-8.
58. Marguerie C, Bunn CC, Beynon HLC, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990;77:1019-38.
59. Mierau R, Dick T, Bartz-Bazzanella P, et al. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996;39:868-76.
60. Arnett FC, Targoff IN, Mimori T, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996;39:1507-18.
61. Frank MB, McCubbin VR, Trieu EP, et al. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137-42.
62. Rutjes SA, Vree Egberts WT, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
63. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985;28:796-803.
64. Lundberg I, Nennesmo I, Hedfors E. A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum 1992;22:127-38.
65. Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl: Clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211-7.
66. Gelpi C, Kanterewicz E, Gratacos J, et al. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996;39:692-7.
67. Brouwer R, Hengstman GJ, Vree E, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
68. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21:115-7.
69. Hengstman GJ, ter Laak HJ, van Engelen BG, et al. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001;70:706.
70. Hengstman GJ, van Engelen BG, Badrising UA, et al. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol 1998;44:423.
71. Vazquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996;39:292-6.
72. Shamim EA, Rider LG, O'Hanlon TP, et al. Clinical, serologic and genetic differences between U.S. Caucasians and Meso-Americans with idiopathic inflammatory myopathy (IIM) [abstract]. Arthritis Rheum 1999;42:S403.
73. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:1257-66.
74. Chmiel JF, Wessel HU, Targoff IN, et al. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol 1995;22:762-5.
75. Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis: Myositisspecific autoantibodies in children. Arthritis Rheum 1994;37:1534-8.
76. Hirakata M, Suwa A, Nagai S, et al. Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999;162:2315-20.
77. Nichols RC, Raben N, Boerkoel CF, et al. Human isoleucyl-tRNA synthetase: Sequence of the cDNA, alternative mRNA splicing, and the characteristics of an unusually long C-terminal extension. Gene 1995;155:299-304.
78. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine: Two additional synthetases are antigenic in myositis. J Immunol 1990;144:1737-43.
79. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
80. Hirakata M, Mimori T, Akizuki M, et al. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 1992;35:449-56.
81. Hirakata M, Suwa A, Takeda Y, et al. Autoantibodies to glycyl-transfer RNA synthetase in myositis. Association with dermatomyositis and immunologic heterogeneity. Arthritis Rheum 1996;39:146-51.
82. Goldstein R, Duvic M, Targoff IN, et al. HLA-D region genes associated with autoantibody responses to Jo-1 (histidyl-tRNA synthetase) and other translation-related factors in myositis. Arthritis Rheum 1990;33:1240-8.
83. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies [comments]. Proc Natl Acad Sci USA 2000;97:9209-14.
84. Targoff IN, Trieu EP, Plotz PH, et al. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992;35:821-30.
85. Venables PJ. Polymyositis-associated overlap syndromes. Br J Rheumatol 1996;35:305-6.
86. Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. N Engl J Med 1975;292:344-7.
87. Lee W, Zimmermann B, Lally EV. Relapse of polymyositis after prolonged remission. J Rheumatol 1997;24:1641-4.
88. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-87.
89. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995;38:1519-23.
90. Tomsic M, Sifrer F. Acute respiratory distress syndrome in a polymyositis patient with the antiJo-1 antibody. Wien Klin Wochenschr 2000;112:728-31.
91. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5.
92. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12:501-8.
93. Kalenian M, Zweiman B. Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies-an interesting association. Clin Diagn Lab Immunol 1997;4:236-40.
94. Takahashi H, Matsumoto T, Abe T, et al. Nihon Rinsho Meneki Gakkai Kaishi [A case of polymyositis with anti-Jo-1 antibody preceded by BOOP] Nihon Rinsho Meneki Gakkai Kaishi 1998;21:87-94 [in Japanese].
95. Grau JM, Miro O, Pedrol E, et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996;23:1921-6.
96. Hirakata M, Suwa A, Satoh S, et al. Clinical features of Japanese patients with anti-aminoacyl tRNA synthetase autoantibodies: The immunogenetic backgrounds [abstract]. Arthritis Rheum 2000;43:S378.
97. Cardon T, Deprez X, Flipo RM, et al. Acute polyarthritis, pulmonary fibrosis and Raynaud's phenomenon disclosing polymyositis with anti-JO-1 antibody associated with Gougerot-Sjogren syndrome. Rev Med Intern 1993;14:744-5.
98. Wasicek CA, Reichlin M, Montes M, et al. Polymyositis and interstitial lung disease in a patient with anti-Jo-1 prototype. Am J Med 1984;76:538-44.
99. Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies:-An evolving spectrum of disease manifestations. Clin Rheumatol 2000;19:371-7.
100. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990;88:241-51.
101. Oddis CV, Medsger Jr TA, Cooperstein LA. A subluxing arthropathy associated with the antiJo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 1990;33:1640-5.
102. O'Neill TW, Maddison PJ. Rheumatoid arthritis associated with myositis and anti-Jo-1 antibody. J Rheumatol 1993;20:141-3.
103. Citera G, Lazaro MA, Maldonado Cocco JA, et al. Apatite deposition in polymyositis subluxing arthropathy. J Rheumatol 1996;23:551-3.
104. Cohen MG, Ho KK, Webb J. Finger joint calcinosis followed by osteolysis in a patient with multisystem connective tissue disease and anti-Jo-1 antibody. J Rheumatol 1987;14:605-8.
105. Garcia-Patos V, Bartralot R, Fonollosa V, et al. Childhood sclerodermatomyositis: Report of a case with the anti-PM/Scl antibody and mechanic's hands. Br J Dermatol 1996;135:613-6.
106. Mitra D, Lovell CL, Macleod TI, et al. Clinical and histological features of 'mechanic's hands' in a patient with antibodies to Jo-1 - A case report. Clin Exp Dermatol 1994;19:146-8.
107. Indart F, Espana A, Idoate MA, et al. A cutaneous lesion associated with primary polymyositis. Arch Dermatol 1993;129:1207-8.
108. Ge Q, Wu Y, Targoff IN. Analysis of epitope reactivity of autoantibodies to glycyl-tRNA synthetase [abstract]. Arthritis Rheum 1994;37:S351.
109. Martin A, Shulman MJ, Tsui FWL. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J 1995;9:1226-33.
110. Raben N, Nichols RC, Dohlman J, et al. A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. J Biol Chem 1994;269:24277-83.
111. Garcia-Lozano JR, Gonzalez-Escribano MF, Rodriguez R, et al. Detection of anti-PL-12 autoantibodies by ELISA using a recombinant antigen; study of the immunoreactive region. Clin Exp Immunol 1998;114:161-5.
112. Bernstein RM, Bunn CC, Hughes GRV, et al. Cellular protein and RNA antigens in autoimmune disease. Mol Biol Med 1984;2:105-20.
113. Hardin JA, Rahn DR, Shen C, et al. Antibodies from patients with connective tissue disease bind specific subsets of cellular RNA-protein particles. J Clin Invest 1982;70:141-7.
114. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity. Nature 1983;304:177-9.
115. ala coexist and are associated with myositis. J Exp Med 1986;163:1281-91.
116. Bunn CC, Mathews MB. Two human tRNAala families are recognized by autoantibodies in polymyositis sera. Mol Biol Med 1987;4:21-36.
117. Brouwer R, Vree Egberts W, Jongen PH, et al. Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum 1998;41:1428-37.
118. Miller FW, Twitty SA, Biswas T, et al. Origin and regulation of a disease-specific autoantibody response: Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 antibodies. J Clin Invest 1990;85:468-75.
119. Targoff IN, Miller FW, Medsger Jr TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-35.
120. Hengstman GJ, van Engelen BG, Vree Egberts WT, et al. Myositis-specific autoantibodies: Overview and recent developments. Curr Opin Rheumatol 2001;13:476-82.
121. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33:1361-70.
122. Hirakata M, Matsuura Y, Suwa A, et al. Immunological and histopathological features of patients with anti-SRP autoantibodies [abstract]. Arthritis Rheum 1997;40:S146.
123. Miller FW. Myositis-specific autoantibodies: Touchstones for understanding the inflammatory myopathies. JAMA 1993;270:1846-9.
124. Miller FW. Signal recognition particle autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier Science BV; 1996. p. 735-40.
125. Leff RL, Burgess SH, Miller FW, et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum 1991;34:1391-6.
126. Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353:1762-3.
127. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 1995;38:123-8.
128. Seelig HP, Renz M, Targoff IN, et al. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum 1996;39:1769-71.
129. Aubry F, Mattei M-G, Galibert F. Identification of a human 17p-located cDNA encoding a protein of the Snf2-like helicase family. Eur J Biochem 1998;254:558-64.
130. Ge Q, Nilasena DS, O'Brien CA, et al. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest 1995;96:1730-7.
131. Seelig HP, Moosbrugger I, Ehrfeld H, et al. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995;38:1389-99.
132. Woodage T, Basrai MA, Baxevanis AD, et al. Characterization of the CHD family of proteins. Proc Natl Acad Sci USA 1997;94:11472-7.
133. Wade PA, Gegonne A, Jones PL, et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999;23:62-6.
134. Zhang Y, LeRoy G, Seelig HP, et al. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-89.
135. Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001;29:2517-21.
136. Mierau R, Dick T, Genth E. Less specific myositis autoantibodies? Ann Rheum Dis 2001;60:810.
137. Hengstman GJ, van Venrooij WJ, Vencovsky J, et al. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000;59:141-2.
138. Reichlin M, Maddison PJ, Targoff IN, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis-overlap syndrome. J Clin Immunol 1984;4:40-4.
139. Ge Q, Frank MB, O'Brien CA, et al. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest 1992;90:559-70.
140. Alderuccio F, Chan EKL, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: A unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med 1991;173:941-52.
141. Ge Q, Wu Y, Trieu EP, et al. Analysis of fine specificity of anti-PM-Scl autoantibodies. Arthritis Rheum 1994;37:1445-52.
142. Briggs MW, Burkard KT, Butler JS. Rrp6p, the yeast homologue of the human PM-Scl 100-kDa autoantigen, is essential for efficient 5.8 S rRNA 3′ end formation. J Biol Chem 1998;273:13255-63.
143. Allmang C, Petfalski E, Podtelejnikov A, et al. The yeast exosome and human PM-Scl are related complexes of 3′ 5′ exonucleases. Genes Dev 1999;13:2148-58.
144. Brouwer R, Pruijn GJ, van Venrooij WJ. The human exosome: An autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Research 2001;3:102-6.
145. Bluthner M, Mahler M, Muller DB, et al. Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med 2000;78:47-54.
146. Ge Q, Wu Y, James JA, et al. Epitope analysis of the major reactive region of the 100-kd protein of PM-Scl autoantigen. Arthritis Rheum 1996;39:1588-95.
147. Blaszczyk M, Jablonska S, Szymanska-Jagiello W, et al. Childhood scleromyositis: An overlap syndrome associated with PM-Scl antibody. Pediatr Dermatol 1991;8:1-8.
148. Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992;71:327-36.
149. Schnitz W, Taylor-Albert E, Targoff IN, et al. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 1996;23:1729-33.
150. Ioannou Y, Sultan S, Isenberg DA. Myositis overlap syndromes. Curr Opin Rheumatol 1999;11:468-74.
151. Craft J, Mimori T, Olsen TL, et al. The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes. J Clin Invest 1988;81:1716-24.
152. Okano Y, Medsger Jr TA. Newly identified U4/6 snRNP-binding proteins by serum autoantibodies from a patient with systemic sclerosis. J Immunol 1991;146:535-42.
153. Okano Y, Targoff IN, Oddis CV, et al. Anti-U5 small nuclear ribonucleoprotein (snRNP) antibodies: A rare anti-U snRNP specificity. Clin Immunol Immunopathol 1996;81:41-7.
154. Rider LG, Targoff IN, Leff RL, et al. Association of autoantibodies to the U5-ribonucleoprotein (U5-RNP) with idiopathic inflammatory myopathy (IIM) [abstract]. Arthritis Rheum 1994;37:S242.
155. Hirakata M, Suwa A, Kuwana M, et al. Immunogenetic features associated with myositis in Japanese patients with anti-Ku autoantibodies [abstract]. Arthritis Rheum 2002;41:S104.
156. Arad-Dann H, Isenberg DA, Shoenfeld Y, et al. Autoantibodies against a specific nuclear RNP protein in sera of patients with autoimmune rheumatic disease associated with myositis. J Immunol 1987;138:2463-8.
157. Arad-Dann H, Isenberg D, Ovadia E, et al. Autoantibodies against a nuclear 56-kDa protein: A marker for inflammatory muscle disease. J Autoimmun 1989;2:877-88.
158. Cambridge G, Ovadia E, Isenberg DA, et al. Juvenile dermatomyositis: Serial studies of circulating autoantibodies to a 56kD nuclear protein. Clin Exp Rheumatol 1994;12:451-7.
159. Lutz JL, Fedczyna TO, Isenberg D, Sperling R, Pachman LM. The association of the DQA1 *0501 allele and antibody to a 56 kD nuclear protein in sera from patients with juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2001;44:S293.
160. Espada G, Confalone Gregorian M, Ortiz Z, et al. Serum autoantibodies in juvenile idiopathic inflammatory myopathies (IIM) in a cohort of Argentine patients [abstract]. Arthritis Rheum 1997;40:S140.
161. Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-74.
162. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.